Status:
COMPLETED
Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Cancer of Lymph Node
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical research study is to learn if the drug Feraheme ® (ferumoxytole) helps researchers most clearly to "see" cancerous lymph nodes on an MRI scan. Researchers also want to learn ...
Detailed Description
Study Participation: If you are found to be eligible, during the following MRI scans, you will pass into a long, narrow tube scanner, which is open at both ends. You will have a total of 3 MRI scans....
Eligibility Criteria
Inclusion
- Enrolled at MDACC, Written consent
- Measurable nodes on the recent cross sectional imaging (CT, MRI. US) or suspicious lymph nodes for metastasis
- Requiring tissue diagnosis (FNA, core biopsy, surgical biopsy, surgical resection), or clinical follow-ups for at least 6 months.
- Any and all primary disease sites in the abdomen and pelvis will be allowed
Exclusion
- Primary or secondary iron overload
- Lactation or pregnant - women of child bearing potential will be excluded
- Contraindications for MRI
- Contraindication or allergy to Feraheme® (based on insert)
- Clinically documented or risk of primary or secondary iron overloading (e.g. History of thalassemia, sickle cell anemia, hereditary hemochromatosis, multiple transfusions with any reason), anemia not caused by iron deficiency
- Age under 18
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 25 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01815333
Start Date
July 1 2013
End Date
July 25 2019
Last Update
October 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030